Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06589440 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Interventions

DRUG: SR-8541A

Sponsor

Stingray Therapeutics